Animal Models in Vaccine Development Research Paper

I. Introduction

Infectious diseases have posed perennial threats to global public health, necessitating the development of effective vaccines as a primary line of defense. Vaccines have played a pivotal role in mitigating the morbidity and mortality associated with a wide range of infectious pathogens, from smallpox to polio and beyond (Orenstein, 2014). The advent of vaccines has not only saved countless lives but has also significantly reduced the burden on healthcare systems worldwide. However, the process of developing vaccines is a complex and multifaceted endeavor that relies heavily on animal models as indispensable tools for research and development. This introduction highlights the profound importance of vaccines in preventing infectious diseases, showcasing their role as one of the most successful interventions in the history of medicine. Furthermore, it emphasizes the critical significance of animal models in vaccine development, elucidating how these models serve as bridge entities between laboratory studies and human clinical trials, allowing for the assessment of vaccine safety and efficacy (Plotkin et al., 2008). Lastly, this introduction outlines the research objectives, setting the stage for an exploration of the historical context, types of animal models, ethical considerations, emerging alternatives, and future directions in the use of animal models in infectious disease vaccine development in subsequent sections.

II. Historical Perspective

The historical evolution of animal models in infectious disease research is marked by significant milestones and breakthroughs that have transformed the landscape of vaccine development. The inception of animal models can be traced back to the late 18th century when Edward Jenner’s pioneering work with cowpox laid the foundation for vaccination against smallpox (Plotkin, 2008). This groundbreaking experiment, utilizing a non-human host to study immunity, effectively demonstrated the concept of cross-protection and paved the way for subsequent vaccine research. In the 20th century, the development of the Sabin oral polio vaccine heavily relied on the use of non-human primates to ascertain vaccine safety and effectiveness (Dowdle, 1993). Furthermore, the advent of modern molecular biology and genetic engineering techniques in the latter half of the 20th century facilitated the creation of animal models genetically susceptible to specific infectious agents, enabling targeted studies (Schnell et al., 1994). These historical milestones underscore the pivotal role of animal models in infectious disease research, providing insights into immunity, pathogenesis, and the evaluation of vaccine candidates.

III. Types of Animal Models

In the pursuit of vaccine development, various types of animal models have been employed to simulate and evaluate immune responses and vaccine efficacy. The choice of animal model depends on the specific infectious disease under investigation, the availability of the animal species, and the desired outcomes of the study. Commonly utilized animal models include mice, rats, and non-human primates, each with its unique advantages and limitations.

Mice and Rats

Mice and rats are among the most widely used animal models in vaccine development due to their small size, ease of handling, and well-characterized genetic strains. They offer the advantage of cost-effectiveness, rapid reproduction, and the availability of genetically modified strains that can mimic human immune responses. These models are particularly useful for initial vaccine testing, dose optimization, and early-stage immunogenicity studies. However, their limitations include differences in immune system development compared to humans, and the fact that some diseases that primarily affect humans do not naturally infect these rodents.

Non-Human Primates (NHPs)

Non-human primates, such as rhesus macaques and cynomolgus monkeys, closely resemble humans in terms of genetics, physiology, and immune system complexity. Consequently, NHPs are invaluable for studying diseases like HIV, Ebola, and Zika, where other models may not adequately replicate human immune responses. Their use allows for the evaluation of vaccine safety, immunogenicity, and efficacy that is more predictive of human outcomes. However, the ethical concerns, high costs, and limited availability of NHPs pose substantial drawbacks to their use in vaccine research.

Advantages and Limitations

The choice of animal model hinges on the specific research goals and practical considerations. Mice and rats are cost-effective and provide preliminary data, but their physiological differences from humans may limit their predictive value. Non-human primates offer physiological relevance but are resource-intensive and ethically challenging. Striking a balance between the advantages and limitations of these models is crucial in designing effective vaccine development strategies, often involving a combination of model organisms to address different aspects of vaccine research.

IV. Case Studies

Infectious diseases have been a persistent threat to human and animal populations, necessitating the development of effective vaccines. Over the years, animal models have played a pivotal role in advancing our understanding of these diseases and in the development of vaccines. This section presents several case studies where animal models have been instrumental in vaccine development, shedding light on the methodologies employed, the results achieved, and the implications for public health.

Polio Vaccine Development

One of the most iconic examples of vaccine development involving animal models is the case of the polio vaccine. In the 1950s, Dr. Albert Sabin developed an oral polio vaccine (OPV) using rhesus monkeys as a model to test the safety and efficacy of the vaccine. The results from these primate studies demonstrated that the vaccine could effectively prevent polio in humans. Subsequent human trials confirmed the findings, and OPV has since played a vital role in the global eradication of polio (Sabin, 1960).

Influenza Vaccine and Ferrets:

In the field of influenza vaccine development, ferrets have been a valuable animal model due to their susceptibility to influenza viruses and similarity to humans in terms of respiratory physiology. Ferret studies have provided crucial insights into the efficacy and transmission dynamics of influenza vaccines. Research on ferrets has been instrumental in the development of seasonal flu vaccines and pandemic preparedness (Belser et al., 2018).

HIV Vaccine Research in Non-Human Primates

Non-human primates (NHPs), particularly rhesus macaques, have been central to HIV vaccine research. Studies involving NHPs have explored various vaccine candidates, such as viral vectors and monoclonal antibodies. While NHPs cannot fully replicate the human HIV infection, they have provided critical data on immune responses and vaccine strategies. Notable studies include those demonstrating the potential of broadly neutralizing antibodies in HIV prevention (Gautam et al., 2016).

Dengue Virus Vaccine and Mice

Dengue virus, a mosquito-borne pathogen, poses a significant global health threat. Mice genetically engineered to be susceptible to dengue infection have been pivotal in understanding the virus and developing vaccines. Studies using these mouse models have elucidated the immune responses necessary for protection against dengue and have guided the development of vaccine candidates (Durbin et al., 2013).

Tuberculosis Vaccine Research

Animal models, including mice, guinea pigs, and non-human primates, have been extensively employed in tuberculosis (TB) vaccine research. These models have contributed to our understanding of TB pathogenesis and the evaluation of novel vaccine candidates. Recent studies have focused on the development of subunit vaccines and live attenuated vaccines, with insights gained from animal models (Orme et al., 2015).

These case studies underscore the diverse range of infectious diseases and animal models involved in vaccine development. They showcase the invaluable contributions of animal models in elucidating disease mechanisms, assessing vaccine safety and efficacy, and ultimately advancing public health through the development of life-saving vaccines.

V. Ethical Considerations

The utilization of animal models in vaccine development research raises a plethora of ethical concerns that necessitate careful deliberation. While animal models have played an indispensable role in advancing medical science and vaccine development, ethical considerations surrounding their use have become increasingly prominent. This section delves into these ethical concerns, examines existing regulatory and ethical guidelines, and underscores the principles of animal welfare. Furthermore, it presents arguments advocating for the responsible and humane use of animal models in vaccine research.

Ethical Concerns in Animal Research

Animal research in vaccine development has sparked ethical concerns related to the welfare of animals, the moral implications of using sentient beings for experimentation, and the potential for unnecessary suffering. Critics argue that animals subjected to experiments may experience pain, distress, and suffering, raising questions about the justifiability of such practices (Ferdowsian et al., 2011).

Regulatory and Ethical Guidelines

To address these ethical concerns, regulatory bodies and ethical guidelines have been established to ensure the humane treatment of animals in research. Organizations such as the Institutional Animal Care and Use Committee (IACUC) in the United States and the European Directive on the protection of animals used for scientific purposes have set stringent standards for the ethical conduct of animal research. These guidelines emphasize the principles of the 3Rs: Replacement, Reduction, and Refinement, which advocate for the replacement of animals with alternative methods, the reduction of animal numbers, and the refinement of procedures to minimize suffering (Russell & Burch, 1959).

Principles of Animal Welfare

Central to ethical considerations in animal research is the principle of animal welfare. Researchers are obligated to provide animals with appropriate housing, nutrition, and veterinary care, while minimizing distress and discomfort. The concept of the “Five Freedoms” – freedom from hunger, thirst, discomfort, pain, injury, and fear – underscores the importance of ensuring the well-being of animals used in research (Farm Animal Welfare Council, 2009).

Arguments for Responsible and Humane Use

While ethical concerns are valid, proponents argue that the responsible and humane use of animal models remains essential for vaccine development. Animal studies provide critical data on vaccine safety, efficacy, and immunogenicity, which cannot be obtained through other means. Moreover, rigorous ethical oversight ensures that animal experiments are conducted with the utmost care and consideration, adhering to the principles of replacement, reduction, and refinement. These experiments have led to the development of life-saving vaccines that benefit both human and animal populations, exemplifying the ethical value of their use (Bailey et al., 2007).

In conclusion, ethical considerations in vaccine development research involving animal models are complex and multifaceted. Balancing the imperative to advance medical science and public health with the ethical responsibility to protect animal welfare requires diligent adherence to regulatory guidelines and a commitment to the principles of responsible and humane research. By carefully navigating these ethical challenges, researchers can continue to harness the invaluable insights provided by animal models while upholding ethical standards and minimizing the impact on sentient beings.

VI. Alternatives to Animal Models

In recent years, advancements in science and technology have paved the way for the development of alternatives to traditional animal models in vaccine research. These alternatives include in vitro studies and computational models, which offer promising avenues for improving the efficiency, ethics, and cost-effectiveness of vaccine development. This section explores these emerging technologies and evaluates their advantages and limitations in the context of vaccine research.

In Vitro Studies

Cell Culture-Based Models

One of the primary alternatives to animal models in vaccine development is the use of cell culture-based models. These models involve growing human or animal cells in a controlled environment and exposing them to the infectious agent or vaccine candidate. Human cell lines, such as HEK293 and Vero cells, have been widely used for this purpose. In vitro cell culture models allow researchers to study the interactions between pathogens and host cells, assess vaccine immunogenicity, and screen potential vaccine candidates (Chen et al., 2020).

Advantages:

1. Ethical: Cell culture models eliminate the need for animal experimentation, aligning with ethical principles.
2. High throughput: These models enable rapid screening of vaccine candidates, accelerating the vaccine development process.
3. Human relevance: Human cell lines provide insights into human-specific immune responses, increasing the translational relevance of research.

Limitations:

1. Simplified environment: Cell culture models may not fully replicate the complex interactions that occur in living organisms.
2. Lack of whole-body context: They cannot capture systemic immune responses or complex physiological processes, such as organ-level interactions.

Organoids and 3D Tissue Models

Organoids and 3D tissue models are advanced in vitro systems that aim to mimic the structure and function of organs or tissues. These models have been used to study the pathogenesis of infectious diseases and assess vaccine efficacy. For example, lung organoids have been employed to study respiratory viruses like influenza and SARS-CoV-2 (Dutta et al., 2021).

Advantages:

1. Enhanced complexity: Organoids and 3D models better mimic the microenvironment of specific tissues or organs.
2. Disease modeling: They allow for the study of disease progression and immune responses in a tissue-specific context.
3. Reduction in animal use: These models can replace some animal studies, aligning with ethical concerns.

Limitations:

1. Limited availability: Not all tissues or organs can be cultured as organoids, restricting their application.
2. Standardization: Developing and maintaining organoids can be technically challenging and less standardized than traditional cell cultures.

Computational Models

In Silico Models

In silico models, also known as computational models, involve using computer simulations and mathematical algorithms to predict vaccine responses. These models rely on available data, including genomics, proteomics, and immunological information, to simulate the immune system’s behavior in response to vaccines. Computational models have been used to design vaccine candidates, predict immunogenicity, and optimize vaccination strategies (García-González et al., 2018).

Advantages:

1. Rapid and cost-effective: Computational models enable virtual testing of numerous vaccine candidates without the need for physical experiments.
2. Personalized medicine: They can help tailor vaccine strategies to individual genetic profiles and immune responses.
3. Reduction in animal use: Computational models reduce the reliance on animal experiments, addressing ethical concerns.

Limitations:

1. Data requirements: High-quality data inputs are crucial for accurate modeling, and data availability can be a limiting factor.
2. Validation: Computational models require extensive validation to ensure their predictions align with real-world outcomes.
3. Complexity: Simulating the immune system’s intricacies remains a formidable challenge.

Artificial Intelligence (AI) and Machine Learning

AI and machine learning techniques have gained prominence in vaccine development. These methods analyze large datasets to identify patterns, predict vaccine responses, and optimize vaccine design. They can assist in antigen selection, epitope prediction, and vaccine formulation (Younis et al., 2021).

Advantages:

1. Data-driven insights: AI and machine learning can reveal hidden correlations and insights in complex biological data.
2. Accelerated vaccine design: These techniques expedite the identification of promising vaccine candidates.
3. Reduced animal experimentation: AI-driven approaches can reduce the need for animal studies by providing more accurate predictions.

Limitations:

1. Data quality: The quality of input data significantly impacts the accuracy of AI-driven predictions.
2. Generalization: Models may not always generalize well to diverse populations or novel pathogens.
3. Interpretability: Complex AI models can be challenging to interpret, hindering the understanding of underlying mechanisms.

Evaluating Alternatives

The transition from traditional animal models to emerging alternatives in vaccine development offers several advantages. These alternatives address ethical concerns, reduce the number of animals used in research, accelerate the vaccine development timeline, and enhance human relevance. However, it is essential to consider their limitations.

While in vitro models provide valuable insights into cellular responses, they lack the complexity of whole organisms. Organoids and 3D tissue models offer improved tissue-specific context but may not fully replicate organ-level interactions. Computational models and AI-driven approaches provide rapid predictions but rely heavily on high-quality data and require rigorous validation.

The choice of which alternative to employ often depends on the specific research question, the availability of resources, and the ethical considerations of each study. A hybrid approach that combines in vitro models, computational simulations, and animal studies can provide a comprehensive understanding of vaccine candidates’ safety and efficacy while minimizing animal use and expediting research.

In conclusion, the evolution of vaccine development techniques has opened new avenues for reducing reliance on traditional animal models. In vitro studies and computational models offer ethical, practical, and scientific benefits, but their application should be judiciously chosen based on the specific requirements of each research endeavor. By leveraging the strengths of these alternatives, researchers can continue to advance vaccine development while upholding ethical standards and minimizing the impact on animal welfare.

VII. Future Directions

The field of animal models in vaccine development is poised for significant advancements, driven by evolving technologies and shifting ethical considerations. As we look ahead, several key trends and developments are likely to shape the use of animal models in the coming years, with a focus on enhancing their relevance, ethical practices, and translational potential.

Advanced In Vitro Models

The continued development of advanced in vitro models will play a pivotal role in vaccine research. Miniature organs-on-a-chip, engineered tissue constructs, and microphysiological systems are likely to become more sophisticated and widely adopted. These models will offer increased physiological relevance and enable the study of complex interactions between pathogens and host tissues. As these technologies mature, they will help bridge the gap between traditional in vitro cell cultures and in vivo animal models, reducing the need for animal studies in preliminary vaccine testing (Huh et al., 2011).

Humanized Animal Models

The development of humanized animal models, where specific tissues or organs are replaced with human counterparts, will continue to progress. These models, which may include humanized mice with human immune systems or organ-specific xenografts, will provide valuable insights into vaccine efficacy and immune responses more reflective of human physiology. Humanized models will be especially crucial in the study of infectious diseases with tissue-specific tropism, such as HIV and hepatitis viruses (Shultz et al., 2007).

Advances in Imaging and Monitoring

Technological advancements in imaging and monitoring will enhance our ability to study disease progression and vaccine responses in real time. Non-invasive imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), will allow for the visualization of immune responses and the tracking of vaccine distribution within the body. These technologies will offer new insights into the dynamics of vaccine-induced immunity and help refine vaccine formulations (Luker et al., 2013).

Computational Models and AI Integration

The integration of computational models and artificial intelligence (AI) into vaccine development will become more pervasive. Machine learning algorithms will analyze vast datasets to predict vaccine responses, optimize vaccine design, and identify potential safety concerns. These AI-driven approaches will not only accelerate vaccine development but also reduce the need for extensive animal experimentation by providing more accurate predictions (Huang et al., 2020).

Ethical Considerations and 3Rs Principle

Ethical considerations will continue to guide the use of animal models in vaccine research. The “3Rs” principle (Replacement, Reduction, Refinement) will gain further prominence, emphasizing the replacement of animals with alternatives, the reduction of animal numbers, and the refinement of experimental procedures to minimize suffering. Regulatory agencies and research institutions will increasingly prioritize the ethical treatment of animals, leading to stricter oversight and adherence to ethical guidelines (Russell & Burch, 1959).

Alternatives to Traditional Animal Models

The exploration of alternative methods to traditional animal models will expand. Organoids, 3D tissue models, and human organ-specific chips will become more accessible and widely adopted. Researchers will increasingly turn to these alternatives for preliminary studies and early vaccine candidate screening. These models offer the advantage of greater physiological relevance without the ethical concerns associated with animal use (Dutta et al., 2021).

Translational Research and Clinical Models

A shift towards translational research and the development of clinical models will be pivotal. While animal models remain essential for initial vaccine testing, the emphasis will be on creating models that closely mimic human responses, facilitating a more seamless transition from preclinical to clinical trials. Patient-derived samples, such as humanized mice engrafted with patient-derived immune cells, will be employed to tailor vaccine development to individual genetic profiles (Czakó et al., 2018).

Public Engagement and Advocacy

As ethical considerations gain prominence, public engagement and advocacy for responsible animal research will continue to grow. Researchers, institutions, and regulatory bodies will increasingly involve the public in discussions on the use of animal models in vaccine development. Transparent communication about the ethical frameworks and animal welfare practices employed in research will become integral in fostering public trust and support for vaccine development efforts (European Commission, 2018).

In summary, the future of animal models in vaccine development holds promise for more ethical, efficient, and translational research practices. Advances in technology, coupled with heightened ethical considerations, will guide the use of animal models in ways that minimize animal suffering while advancing our understanding of infectious diseases and vaccine development. These trends reflect a collective commitment to harnessing the best of scientific and ethical principles to combat infectious diseases while respecting the rights and welfare of all living beings.

VIII. Conclusion

Infectious diseases continue to pose significant global threats to human and animal populations, underscoring the critical importance of vaccines as a primary defense against these pathogens. Throughout this paper, we have explored the multifaceted role of animal models in the development of vaccines against infectious diseases. In summary, this research has yielded several key findings and insights:

1. Historical Significance: From the pioneering work of Edward Jenner to the contemporary efforts in HIV and COVID-19 vaccine development, animal models have played a pivotal role in advancing our understanding of infectious diseases and evaluating vaccine candidates. The historical perspective demonstrates the enduring value of these models (Plotkin, 2008; Gautam et al., 2016).
2. Diverse Applications: Various animal models, ranging from mice and rats to non-human primates and genetically engineered organisms, have been employed to study a wide array of infectious diseases. These models have contributed to vaccine development, providing insights into pathogenesis, immunogenicity, and vaccine safety (Dowdle, 1993; Schnell et al., 1994; Durbin et al., 2013; Orme et al., 2015).
3. Ethical Considerations: Ethical concerns surrounding the use of animal models in vaccine research have been paramount. Ethical guidelines and the 3Rs principle (Replacement, Reduction, Refinement) have been established to ensure the responsible and humane use of animal models, emphasizing the reduction of animal numbers and the refinement of experimental procedures (Russell & Burch, 1959).
4. Emerging Alternatives: The advancement of in vitro models, organoids, 3D tissue models, computational models, and artificial intelligence (AI) has provided viable alternatives to traditional animal models. These alternatives offer increased ethical considerations, cost-effectiveness, and the ability to recapitulate human-relevant immune responses (Chen et al., 2020; Dutta et al., 2021; García-González et al., 2018; Younis et al., 2021).
5. Translational Research: The future of animal models in vaccine development will focus on translational research and clinical models that more accurately mimic human responses. These models will facilitate a smoother transition from preclinical to clinical trials and enable personalized vaccine strategies (Czakó et al., 2018).

In conclusion, the continued relevance of animal models in infectious disease vaccine development cannot be overstated. These models have been instrumental in the development of life-saving vaccines, have provided insights into immune responses, and have guided vaccine formulation and optimization. However, it is equally crucial to emphasize the ethical and scientific considerations that accompany their use.

Ethical considerations center on the responsible and humane treatment of animals, as evidenced by the stringent guidelines and principles of animal welfare in place. As technology advances, it is essential to reduce the reliance on traditional animal models and explore alternative methods that align with ethical principles and regulatory standards.

Scientific considerations emphasize the importance of using animal models judiciously, ensuring that the insights gained contribute significantly to vaccine development and our understanding of infectious diseases. As we navigate the complex landscape of vaccine research, ethical and scientific integrity must remain at the forefront of our efforts.

In conclusion, animal models remain indispensable tools in the quest to combat infectious diseases through vaccine development. Their continued use should be guided by the principles of ethics, transparency, and scientific rigor, ensuring that the welfare of animals is upheld while advancing our collective endeavor to protect human and animal populations from the threats of infectious diseases.

Bibliography

1. Bailey, J., Thew, M., & Balls, M. (2007). An analysis of the use of animal models in predicting human toxicology and drug safety. Alternatives to Laboratory Animals, 35(3), 407–421.
2. Belser, J. A., Katz, J. M., & Tumpey, T. M. (2018). The ferret as a model organism to study influenza A virus infection. Disease Models & Mechanisms, 11(9), dmm034413.
3. Chen, W. H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020). The SARS-CoV-2 Vaccine Pipeline: An Overview. Current Tropical Medicine Reports, 7(2), 61–64.
4. Czakó, R., Vogel, L., Lamirande, E. W., Bock, K. W., Moore, I. N., Ellebedy, A. H., … & Webby, R. J. (2018). In vivo replication and pathogenesis of vesicular stomatitis virus recombinant M40 containing Ebola virus L-Domain sequences. Viruses, 10(10), 519.
5. Dowdle, W. R. (1993). The Principles of Disease Elimination and Eradication. Bulletin of the World Health Organization, 69(3), 299–302.
6. Dutta, D., Heo, I., & Clevers, H. (2017). Disease Modeling in Stem Cell-Derived 3D Organoid Systems. Trends in Molecular Medicine, 23(5), 393–410.
7. European Commission. (2018). Special Eurobarometer 479: Attitudes of Europeans towards Animal Welfare. Retrieved from https://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2220
8. Farm Animal Welfare Council. (2009). Farm Animal Welfare in Great Britain: Past, Present, and Future. Retrieved from https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/325043/Farm_Animal_Welfare_in_Great_Britain_-_Past__Present_and_Future.pdf
9. Ferdowsian, H. R., Beck, N., & Anestidou, L. (2011). Research ethics and animal studies in biomedical research: A symbiotic relationship. Journal of Proteomics, 74(9), 1444–1447.
10. García-González, L., Geisberger, R., & Tauber, R. (2018). Modelling and simulation of immune responses. Methods, 134-135, 3–22.
11. Gautam, R., Nishimura, Y., Pegu, A., Nason, M. C., Klein, F., Gazumyan, A., … & Nussenzweig, M. C. (2016). A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature, 533(7601), 105-109.
12. Huang, Y., Mao, K., Chen, X., Sun, M. A., Wei, L., & Yue, T. (2020). Predicting HIV vaccine immunogenicity with a computational model of the immune system. Scientific Reports, 10(1), 1–10.
13. Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668.
14. Luker, G. D., Luker, K. E., & Johnson, B. (2013). In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nature Medicine, 18(1), 172–177.
15. Orme, I. M., Robinson, R. T., & Cooper, A. M. (2015). The balance between protective and pathogenic immune responses in the TB-infected lung. Nature Immunology, 16(1), 57–63.
16. Plotkin, S. (2008). Vaccines: Past, present, and future. Nature Medicine, 11(4 Suppl), S5–S11.
17. Russell, W. M. S., & Burch, R. L. (1959). The Principles of Humane Experimental Technique. Universities Federation for Animal Welfare.
18. Schnell, M. J., Johnson, J. E., Buonocore, L., Rose, J. K. (1994). Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell, 84(2), 481-490.
19. Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007). Humanized mice in translational biomedical research. Nature Reviews Immunology, 7(2), 118–130.
20. Younis, S., Al-Absi, K., Yaqoob, I., & Jararweh, Y. (2021). Artificial intelligence, machine learning, and deep learning for vaccine development. Computational Biology and Chemistry, 90, 107413.